Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance, with a significant increase in net income and revenue driven by collaboration agreements. Product development updates, including the commercial launch of REDEMPLO and partnerships with Novartis and Sarepta, are promising. However, management's avoidance of specific questions in the Q&A might cause slight concern. The market cap suggests moderate volatility, leading to a positive stock price movement prediction of 2% to 8% over the next two weeks.
Key Financial Performance
Net Income $30.8 million for the quarter ended December 31, 2025, compared to a net loss of $173.1 million in the prior year. This represents a significant improvement, driven by revenue from license and collaboration agreements.
Revenue $264 million for the quarter, primarily driven by license and collaboration agreements with Sarepta and Novartis. This is a substantial increase compared to the prior year, attributed to milestone payments and upfront payments from collaborations.
Operating Expenses $223 million for the quarter, up from $164 million in the prior year. The increase is due to higher R&D expenses (up $40 million) and SG&A expenses (up $19 million), driven by clinical trial costs and commercialization investments.
Cash and Investments $917 million as of December 31, 2025, not including additional milestone payments and financing transactions completed in early 2026. This reflects a strong financial position.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA approval of REDEMPLO: REDEMPLO was approved as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
Launch of REDEMPLO: REDEMPLO was launched independently in the U.S. with over 100 prescriptions received within 10 weeks of launch.
Expansion of cardiometabolic pipeline: Ongoing Phase III study of zodasiran for homozygous familial hypercholesterolemia (HoFH) and early clinical data for obesity treatments ARO-INHBE and ARO-ALK7.
Development of ARO-DIMER-PA: Initiated Phase I/II study for mixed hyperlipidemia, targeting PCSK9 and APOC3 genes.
International approvals for REDEMPLO: REDEMPLO received approval in Canada and China, with plans for independent marketing in Canada and partnership with Sanofi in China.
Potential EU and UK launch: Pending regulatory review, REDEMPLO may launch in select EU countries and the UK later this year.
Financial performance: Net income of $30.8 million for the quarter, driven by $264 million in revenue from collaborations and initial commercial sales of REDEMPLO.
Strengthened balance sheet: Raised $1.33 billion through licensing agreements, milestone payments, and public offerings.
Collaboration with Novartis: Entered a global licensing agreement for ARO-SNCA, receiving $200 million upfront and potential milestone payments up to $2 billion.
Focus on CNS portfolio: Dosed first subjects in Phase I/II trial for ARO-MAPT targeting tauopathies, including Alzheimer’s disease.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval and Commercialization Challenges: The company has received regulatory approval for REDEMPLO in the U.S., Canada, and China, but faces challenges in launching the product in additional markets such as the EU and the U.K., pending regulatory review and approval. This could delay revenue generation and market penetration.
Market Competition: REDEMPLO faces competition from existing treatments like olezarsen, which could impact its market share and adoption rates. Additionally, the company is entering a competitive landscape in obesity and cardiovascular disease treatments.
Supply Chain and Distribution: The company has only had REDEMPLO in the channel for 10 weeks, and early distribution challenges could impact initial sales and customer satisfaction.
Clinical Development Risks: The company is heavily reliant on the success of its ongoing Phase III studies for plozasiran and other pipeline candidates. Any delays or failures in these trials could significantly impact future revenue and strategic objectives.
Financial Sustainability: While the company has strengthened its balance sheet, it remains dependent on achieving commercial success and meeting milestones in its collaboration agreements to sustain operations and fund future developments.
Regulatory and Payer Risks: Although initial payer feedback for REDEMPLO has been positive, there is still uncertainty around broader payer acceptance and coverage, which could impact patient access and sales.
Early-Stage Pipeline Uncertainty: The company’s early-stage programs, such as ARO-INHBE and ARO-ALK7 for obesity, show promise but are still in early phases of development. There is substantial work ahead to validate these candidates, and failure could impact long-term growth.
Economic and Market Conditions: Broader economic uncertainties and market conditions could impact the company’s ability to achieve its financial and strategic goals, particularly in launching new products and expanding its market presence.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Commercial sales progress for REDEMPLO: Arrowhead anticipates continued progress in commercial sales of REDEMPLO, a drug approved for familial chylomicronemia syndrome (FCS). Early trends in prescription payer interactions and shipments have been encouraging, with over 100 prescriptions received to date. The company expects further geographic expansion and payer engagement to support growth.
Phase III SHASTA-3 and SHASTA-4 studies of plozasiran: Arrowhead expects a Q3 2026 readout of Phase III SHASTA-3 and SHASTA-4 studies for plozasiran in patients with severe hypertriglyceridemia (SHTG). The company believes this could represent a $3 billion to $4 billion commercial opportunity.
ARO-DIMER-PA clinical trial: Interim data for ARO-DIMER-PA, targeting PCSK9 and APOC3 for LDL and triglyceride lowering, is expected in the second half of 2026. This drug may address mixed hyperlipidemia, a condition affecting approximately 20 million patients in the U.S.
ARO-INHBE and ARO-ALK7 obesity programs: Additional data from ARO-INHBE and ARO-ALK7 obesity programs are expected in 2026. Early results have shown promising weight loss and fat reduction outcomes, particularly in combination with tirzepatide for obese patients with type 2 diabetes.
ARO-MAPT CNS program: Interim clinical data for ARO-MAPT, targeting tau protein for Alzheimer's disease and tauopathies, is anticipated in 2026. This program utilizes a proprietary blood-brain barrier delivery system and could validate Arrowhead's CNS pipeline.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide a breakdown of the different categories of patients transitioning to REDEMPLO and reasons for switching?
A:The vast majority of patient origination is from the APOC3-naive segment, with the remaining balance split roughly 50-50 between those transitioning from expanded access and those switching. Switches are driven by efficacy and safety concerns.
Q:Have you had discussions with the FDA about the development path for obesity and timelines for Phase II?
A:Discussions with the FDA are expected around the middle of the year, and an IND filing will follow shortly thereafter. Not all cohort data is required before determining the next steps.
Q:What are your expectations for the ARO-DIMER-PA asset in terms of LDL-C reduction and its impact on advancing the asset?
A:A reduction in LDL and triglycerides of around 40%-50% would be encouraging. This level of reduction, even if less than plozasiran, would likely be sufficient to advance the asset.
Q:What are your thoughts on potential pricing for INHBE and ALK7?
A:It is too early to speculate on pricing as the understanding of how these drug candidates work in various patient populations is still developing.
Q:Can you provide details on pancreatitis event rates in the SHASTA-3 and SHASTA-4 trials?
A:No additional details on event rates or the number of events were provided, but events are being observed. The placebo event rate is expected to be similar to the olezarsen core trials.
Q:Have payer discussions for REDEMPLO included SHTG, and is the FCS price point appropriate for SHTG?
A:Specific payer discussions were not disclosed. The focus is on ensuring coverage for FCS patients. The SHTG market is large, but the initial target is high-risk individuals with triglycerides above 880 or a history of pancreatitis.
Q:What data from the ARO-MAPT program would increase confidence in the CNS platform?
A:Key data includes safety and CSF knockdown in healthy volunteers, and downstream biomarkers like phospho tauopathies in patients. Tau PET signal reduction in patients would be very encouraging.
Q:How will you report cost-of-goods-sold (COGS) and REDEMPLO product sales?
A:COGS prior to launch are included in R&D. Product revenue and sales will be disclosed when they become meaningful drivers.
Q:What are your expectations for monotherapy weight loss in obese nondiabetic patients with the ALK7 program?
A:There are no specific expectations; the studies are hypothesis-generating. Monotherapy cohorts have been added to the INHBE study and likely to the ALK7 study as well.
Q:Can you provide a breakdown of EAP versus non-EAP patients for REDEMPLO prescriptions?
A:No further details were provided beyond the majority being APOC3-naive, with the balance evenly split between expanded access program transitions and switches.
Q:What are the expectations for data sets and platform expansion over the next 12-18 months?
A:No specific guidance was provided, but there is ongoing development of the platform and potential new candidates.
Q:How many of the 100 REDEMPLO prescriptions are expected to convert to paid drug, and what is the timeline?
A:A significant proportion of prescriptions are expected to convert to drug shipments within a couple of weeks. The process varies by patient, insurance, and prior authorization.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers to questions about pricing for INHBE and ALK7, pancreatitis event rates in SHASTA-3 and SHASTA-4, specific payer discussions for REDEMPLO, and the breakdown of EAP versus non-EAP patients. Additionally, no guidance was given on expectations for data sets and platform expansion over the next 12-18 months.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APOC class
ARO DIMER
Alzheimer patient
Arrowhead
BBB
DIMER PA
DM
FDA approval
Head
II study
III study
Novartis
Phase II
Phase III
RD
SHASTA study
Sarepta
TGs
TRiM platform
achievement
coupon
fat
health care
loss reduction
note
number
offering
patient Phase
plozasiran
premium
prescription
program patient
remainder
self
start
stock
system
team
transaction
triglyceride adult
ARWR Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript
Positive2-6
The earnings call reveals strong financial performance, with a significant increase in net income and revenue driven by collaboration agreements. Product development updates, including the commercial launch of REDEMPLO and partnerships with Novartis and Sarepta, are promising. However, management's avoidance of specific questions in the Q&A might cause slight concern. The market cap suggests moderate volatility, leading to a positive stock price movement prediction of 2% to 8% over the next two weeks.
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript
Positive11-25
The earnings call highlights strong financial performance, strategic partnerships, and promising product development, such as the plozasiran launch and multiple drug pipelines. Despite some uncertainties in clinical trial outcomes and regulatory claims, the overall sentiment remains positive due to solid financial health, strategic partnerships, and optimistic guidance. The market cap suggests a moderate reaction, likely resulting in a positive stock price movement of 2% to 8% over the next two weeks.
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-10
ARWR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
